This is an open, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets in patients with chronic graft-versus-host disease
Voluntary and signed informed consent, good compliance;
Age 18-70 years old; Karnofsky Performance Scale (KPS) ≥60 points; Life expectancy ≥ 6months.
Received allogeneic hematopoietic stem cell transplantation;
Diagnosis of moderate-to-severe chronic graft-versus-host disease (cGVHD)
Currently present or occured other malignancies within 3 years prior to first administration;
Known or suspected active acute graft versus host disease (aGVHD);
Presence of infection requiring treatment within 7 days prior to randomization;
Failed allogeneic hematopoietic stem cell transplantation within 6 months or 2 prior allogeneic hematopoietic stem cell transplants;
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Lead sponsor